Forward agenda is conversion work: management's own stated priorities are about turning already-secured growth into resu
The model's full reasoning — Q4 2023 call → NO我们根据提供的财报电话会议记录，判断管理层的未来议程是否主要是将已获得的增长转化为交付成果，以及报告结果是否尚未反映该增长。 首先，阅读管理层关于未来工作的描述。在电话会议中，Michael Castagna 和 Steven Binder 多次提到： - 关于 Tyvaso DPI：他们提到“record production on Tyvaso cartridges”，以及“high-speed fill finish line in terms of qualification”和“PPQ”即将开始，以生产更高产量。这表明他们正在执行已存在的制造合同（与 United Therapeutics 的合作），属于转化工作。 - 关于 Afrezza 和内分泌业务：他们提到“optimized our sales force footprint”和“key account managers”以支持现有产品，但更多是围绕未来数据（INHALE-1 和 INHALE-3）的临床读出，这些是尚未获得的结果，属于追求新机会。 - 关于 MNKD-101（clofazimine）：他们提到“file the R&D here in March and kick off the trial in June”，这是启动新试验，属于追求新机会，而非转化已获得的业务。 - 关于 MNKD-201：他们提到“IND will be filed”和“Phase 1 clinical trial”，同样是新试验。 然而，管理层明确表示 Tyvaso DPI 的制造是“as much as we can around the clock”，并且“we are making as much as we can”，这属于执行已存在的合同。此外，他们提到“we have record production in Q4”和“hopefully equal record production in Q1”，表明他们正在将已获得的订单转化为交付。 关于已获得的增长是否已反映在结果中：管理层说“2023 was a year of substantial revenue growth”和“total revenues doubled”，但 Tyvaso DPI 的 royalty 和合作收入在增长，但尚未完全反映？他们提到“we sold 1% of our Tyvaso royalty”以获得现金，但这是融资而非运营。他们还说“the just-reported numbers describe a smaller business than the one management is already working to deliver”，但具体来说，他们提到“we have never seen a better time for MannKind”和“we are financially prime”，但并未明确说已获得的业务尚未反映在数字中。 关键点：管理层在回答问题时，多次强调他们正在执行 Tyvaso DPI 的制造合同，这是已获得的业务。但他们的未来议程中，大部分是关于临床试验的启动和读出，这些是追求新机会，而非转化已获得的增长。此外，他们提到“we will wait to see the results from the INHALE-3 and INHALE-1 clinical trials for Afrezza before deciding whether to increase promotional spend”，这表明他们尚未将潜在增长视为已获得。 因此，管理层的未来议程主要是关于临床试验和潜在机会，而非转化已获得的业务。虽然 Tyvaso DPI 制造是转化，但整体上，他们更多是在追求新机会。 此外，他们提到“we have multiple shots on goal”和“pipeline”，这更多是追求。 因此，答案应为 NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| EFXT | Enerflex Ltd. | Q3 2023 | 2023-11-09 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| HY | Hyster-Yale Materials Handling, Inc. | Q3 2021 | 2021-11-06 | D |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
EVGO · Q2 2022 → YESThe question is about whether management's forward agenda is about converting already secured growth into results, and if the reported results don't yet reflect that growth. YES The forward agenda centers on converting already-secured growth: the Pilot-GM eXtend deal (up to 2,000 stalls + 500 locations) is described as recently announced and exceeding IRR hurdles, with EVgo procuring, constructing, operating, and maintaining the assets on a capital-light basis; the 2022 guidance is affirmed and tracked, with heavier second-half loads explicitly tied to PFJ and fleet contractual revenues kicking in Q3/Q4 (some already baked into forecasts after late-2021 negotiations); current stall counts (2,397 in operation/under construction, 3,669 pipeline) and throughput explicitly exclude the 2,000-stall Pilot contribution; Delta supply agreement covers the first phase of the PFJ deal through 2026; and execution themes include ramping stalls, commissioning, fleet onboarding, and regulatory credit recognition tied to these committed contracts. The reported Q2 results ($9.1M revenue, 10.
BRBR · Q4 2023 → YESThe question is: On this call, when management describes what the company is focused on over the coming quarters — its own stated priorities, tasks, and to-do list — is that forward agenda substantial...YES The forward agenda centers on converting already-secured growth by ramping production (17% growth in fiscal '23, 20%+ planned for '24 via new co-mans and Michael Foods startup in December), restarting promotions and marketing once supply allows, and scaling the transformed co-man network to fulfill committed demand — all while noting tight supply dynamics persisting through most of fiscal '24. Management explicitly conveys that the reported FY '23 results (22% sales growth, 25% EBITDA growth) reflect only a portion of the secured trajectory, with the bulk of new capacity contributions and promotional lift still ahead in fiscal '24, treating 10-15% sales and 6-15% EBITDA guidance as the meaningful next step rather than a routine continuation.
EFXT · Q3 2023 → YESThe question is: Does management describe their focus over coming quarters as converting already secured growth into delivered results, AND do they convey that reported results don't yet meaningfully ...YES The transcript shows management's forward agenda centers on converting secured growth: executing on the $1.6 billion Engineered Systems backlog for 2024 revenue visibility, realizing remaining USD 60 million synergies from Exterran integration, consolidating facilities, and prioritizing debt reduction plus operational efficiency. They describe this as turning already-committed 2024 activity into delivered results, with the backlog providing "strong visibility into revenue generation and business activity levels for 2024" and embedded margins in line with mid-teens targets.